356 related articles for article (PubMed ID: 15541343)
21. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.
Valente S; Tardugno M; Conte M; Cirilli R; Perrone A; Ragno R; Simeoni S; Tramontano A; Massa S; Nebbioso A; Miceli M; Franci G; Brosch G; Altucci L; Mai A
ChemMedChem; 2011 Apr; 6(4):698-712. PubMed ID: 21374822
[TBL] [Abstract][Full Text] [Related]
22. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
23. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
24. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
Lee KW; Kim JH; Park JH; Kim HP; Song SH; Kim SG; Kim TY; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
Anticancer Res; 2006; 26(5A):3429-38. PubMed ID: 17094463
[TBL] [Abstract][Full Text] [Related]
26. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
[TBL] [Abstract][Full Text] [Related]
27. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
28. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Law AY; Lai KP; Lui WC; Wan HT; Wong CK
Exp Cell Res; 2008 Oct; 314(16):2975-84. PubMed ID: 18652825
[TBL] [Abstract][Full Text] [Related]
30. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
Chen J; Du C; Kang J; Wang J
Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
[TBL] [Abstract][Full Text] [Related]
31. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
[TBL] [Abstract][Full Text] [Related]
32. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
[TBL] [Abstract][Full Text] [Related]
33. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Dallavalle S; Cincinelli R; Nannei R; Merlini L; Morini G; Penco S; Pisano C; Vesci L; Barbarino M; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2009 May; 44(5):1900-12. PubMed ID: 19084294
[TBL] [Abstract][Full Text] [Related]
35. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
36. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
[TBL] [Abstract][Full Text] [Related]
38. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
Wong JC; Hong R; Schreiber SL
J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
[TBL] [Abstract][Full Text] [Related]
39. Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Bray MR; Patel DV; Xiao XX
Bioorg Med Chem Lett; 2005 Apr; 15(8):1969-72. PubMed ID: 15808449
[TBL] [Abstract][Full Text] [Related]
40. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
Lu Q; Wang DS; Chen CS; Hu YD; Chen CS
J Med Chem; 2005 Aug; 48(17):5530-5. PubMed ID: 16107152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
